Zymeworks (ZYME) Reports Strong Phase 1 Results for ZW191 in Ovarian Cancer

gurufocus.com · 2026-10-24

On October 24, 2026, Zymeworks Inc. (NASDAQ: ZYME) announced promising Phase 1 clinical trial outcomes for its antibody-drug conjugate ZW191, targeting folate r

Read the full story at gurufocus.com →